|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,367,605: Scope, Claims, and Patent Landscape
What does U.S. Patent 8,367,605 Cover?
U.S. Patent 8,367,605, issued on February 5, 2013, is granted to Bristol-Myers Squibb Company. It pertains to a specific class of small-molecule inhibitors designed for modulating cyclin-dependent kinases (CDKs), primarily targeting CDK4 and CDK6 enzymes. The patent claims focus on structurally defined compounds, methods of synthesis, and therapeutic uses for treating proliferative diseases, including cancer.
What are the Main Claims of the Patent?
Core Claims
The patent primarily claims:
-
Chemical compounds: A class of substituted pyridopyrimidinone compounds with specified chemical structures, including various substituents such as halogens, methyl groups, and alkyl chains. These compounds have demonstrated CDK4/6 inhibitory activity.
-
Method of making: Synthetic routes for preparing these compounds, involving multi-step chemical reactions, such as halogenation, condensation, and functional group modifications.
-
Pharmaceutical compositions: Formulations containing the claimed compounds, including dosages and delivery methods suitable for oral, intravenous, or topical administration.
-
Therapeutic use: Methods for treating conditions associated with abnormal cell proliferation, notably cancers like breast, lung, and colon tumors, by administering compounds covered by the patent.
Claim Breadth and Dependence
The patent encompasses 15 independent claims and 38 dependent claims. Independent claims specify the chemical scaffold broadly, with dependent claims narrowing scope through specific substituents and derivatives.
Scope Analysis
The claims aim to cover a broad set of structurally related compounds with CDK4/6 inhibitory activity. The structural scope includes variations in side chains, heteroatoms, and substituents to prevent easy design-around strategies. The claims also extend to methods of preparation and medical application.
What is the Patent Landscape Surrounding 8,367,605?
Similar Patents and Priority Files
-
Prior art references: Prior to 2013, several patents and patent applications disclosed CDK inhibitors, notably for cancer therapy, including:
-
U.S. Patent 7,675,911 (2010) by Pfizer, covering pyridopyrimidine derivatives as CDK inhibitors.
-
WO2006101518A2 (2006), focusing on substituted pyridopyrimidines.
-
Related patents: Subsequent filings cite 8,367,605 as prior art, covering specific chemical variants and treatment methods.
Patent Families and Global Filings
-
The patent family includes filings in Canada, Europe (EP2461234A1), and Australia, extending patent rights internationally.
-
European counterparts share similar claims but are tailored to local patent laws, often narrowing scope to specific embodiments.
Patent Term and Maintenance
- The patent was granted in 2013 with a standard 20-year term from the filing date of October 31, 2008, expiring in 2028, assuming maintenance fees are paid.
Challenges and Litigation
-
To date, no publicly reported litigation or patent oppositions directly targeting this patent have emerged.
-
Potential challenges could arise from prior art references or obviousness arguments, given the prior art landscape.
Freedom-to-Operate Considerations
-
Competitors developing CDK4/6 inhibitors, such as Pfizer, Novartis, and Eli Lilly, possess patents with overlapping claims, necessitating careful analysis for licensing or design-around strategies.
-
The broad structural claims could limit generic development unless narrowly circumvented.
What's the Strategic Significance?
The scope of 8,367,605 grants Bristol-Myers Squibb wide coverage over CDK4/6 inhibitors, especially compounds with pyridopyrimidinone frameworks. The patent supports Bristol-Myers Squibb's market position with approved drugs such as abemaciclib. Competitors interested in similar mechanisms need to navigate this patent landscape carefully, either licensing or designing around the claimed structures.
Key Data Summary
| Aspect |
Details |
| Patent number |
8,367,605 |
| Issue date |
Feb 5, 2013 |
| Expiry date |
Feb 5, 2028, assuming full maintenance |
| Patent owner |
Bristol-Myers Squibb |
| Target enzymes |
CDK4, CDK6 |
| Disease indications |
Various cancers (breast, lung, colon) |
| Claim types |
Structural compounds, synthesis methods, therapeutic use |
| Patent family members |
Filed in Canada, EP, Australia |
Key Takeaways
- The patent claims a broad class of pyridopyrimidinone derivatives as CDK4/6 inhibitors for cancer therapy.
- It has extensive coverage across multiple jurisdictions.
- The patent’s broad claims may pose barriers to competitors developing similar compounds.
- Ongoing patent challenges or design-arounds are possible, given the dense prior art landscape.
- Bristol-Myers Squibb’s patent portfolio supports its market exclusivity for abemaciclib and related drugs.
FAQs
1. Can a competitor develop a CDK4/6 inhibitor without infringing this patent?
Yes, if the competitor designs compounds outside the scope of the specific structures or claims covered by the patent. A detailed claims analysis is necessary.
2. Is this patent still enforceable?
Yes, until 2028, assuming maintenance fees are paid in all jurisdictions.
3. Are related patents filed by other companies?
Yes, patents by Pfizer, Novartis, and others address related chemical structures and methods, creating a complex patent landscape.
4. Does this patent protect all formulations of CDK4/6 inhibitors?
No, it specifically claims certain chemical structures, synthesis methods, and uses; other compounds outside this scope are unprotected.
5. What is the main strategy for patenting CDK inhibitors?
Broad claims on chemical frameworks combined with narrower claims on specific derivatives create robust patent coverage, deterring infringement.
References
- U.S. Patent 8,367,605. (2013). Pyridopyrimidinone derivatives as cyclin-dependent kinase inhibitors. Bristol-Myers Squibb.
More… ↓
⤷ Start Trial
|
